Trial Profile
Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs FP 1039 (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel; Pemetrexed
- Indications Malignant-mesothelioma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 May 2019 Results assessing GSK3052230 in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma (n=36) published in the Investigational New Drugs
- 10 Nov 2017 Status changed from active, no longer recruiting to completed.
- 05 Oct 2017 Planned End Date changed from 28 Sep 2017 to 24 Oct 2017.